Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Assets (2016 - 2025)

Rocket Pharmaceuticals (RCKT) has disclosed Non-Current Assets for 10 consecutive years, with $137.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 7.89% to $137.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $568.5 million through Dec 2025, down 6.72% year-over-year, with the annual reading at $137.7 million for FY2025, 7.89% down from the prior year.
  • Non-Current Assets hit $137.7 million in Q4 2025 for Rocket Pharmaceuticals, down from $140.4 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $188.1 million in Q4 2023 to a low of $104.7 million in Q1 2021.
  • Historically, Non-Current Assets has averaged $138.5 million across 5 years, with a median of $145.2 million in 2025.
  • Biggest five-year swings in Non-Current Assets: soared 78.87% in 2022 and later decreased 20.52% in 2024.
  • Year by year, Non-Current Assets stood at $105.0 million in 2021, then skyrocketed by 78.87% to $187.7 million in 2022, then grew by 0.2% to $188.1 million in 2023, then fell by 20.52% to $149.5 million in 2024, then dropped by 7.89% to $137.7 million in 2025.
  • Business Quant data shows Non-Current Assets for RCKT at $137.7 million in Q4 2025, $140.4 million in Q3 2025, and $143.8 million in Q2 2025.